Significant Q3 2008 transactions and events
The commercial launch of ORALAIR(R) Grasses for adults took place in Germany at the end of July. The product was well received by allergy professionals. However, ORALAIR(R) Grasses' sales over the quarter were not significant since the launch occurred after the pollen season.
The marketing licence of ORALAIR(R) Grasses in its paediatric indication, which should be delivered by the German agency before the end of the year, will mark the start of the European mutual recognition registration procedure of the product.
The roll-out of the ORALAIR(R) Mites phase II/III pivotal study, initiated at the end of 2007, is continuing satisfactorily.
Lastly, Stallergenes expanded its product range following the exclusive agreement announced on 7 October for the promotion and distribution in Europe of an adrenalin auto-injector, jointly developed and manufactured by Catalent and The Medical House PLC.
Outlook for the current financial year
Due to the strong sales recorded over the quarter, the Company is in a position, for the second time this year, to review its 2008 full-year sales guidance upwards. Sales growth in the region of 14% is now expected.
As a result, at the same time as implementing a significant research and development expenditure programme, the Group's guidance is for full-year net profit slightly higher than in the previous financial year, as well as a further improved financial position, which will enhance its development resources.
Stallergenes is a European biopharmaceutical company dedicated to
desensitisation therapies for the prevention and treatment of
allergy-related respiratory diseases, e.g. rhino-conjunctivitis and
allergic asthma. A pioneer and leader in sublingual desensitisation
treatment, Stallergenes devotes 20% in raw data of its sales to Research
and Development and is actively involved in the development of a new
Copyright©2008 PR Newswire.
All rights reserved